The efficacy of Elbasvir/Grazoprevir fixed-dose combination for 8 weeks in HCV treatment and health-related quality of life (HRQoL) in treatment-naïve, non-cirrhotic, genotype 4-infected patients (ELEGANT-4)

Ahmad AlEid, Areej Al Balkhi, Adel Qutub, Shahem Abbarh, Abed AlLehibi, Abdullah Almtawa, Nawwaf Al Otaibi, Ahmed AlGhamdi, Adel AlGhamdi, Abdulrahman Alamr, Shameem Ahmad, Khalid Al Sayari, Bashaar Al Ibrahim, Abdullah AlKhathlan

Open source

DOI: 10.4103/sjg.sjg_374_21
Published: 2022-05
Container: Saudi Journal of Gastroenterology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.4103/sjg.sjg_374_21,
  title = {The efficacy of Elbasvir/Grazoprevir fixed-dose combination for 8 weeks in HCV treatment and health-related quality of life (HRQoL) in treatment-naïve, non-cirrhotic, genotype 4-infected patients (ELEGANT-4)},
  author = {Ahmad AlEid and Areej Al Balkhi and Adel Qutub and Shahem Abbarh and Abed AlLehibi and Abdullah Almtawa and Nawwaf Al Otaibi and Ahmed AlGhamdi and Adel AlGhamdi and Abdulrahman Alamr and Shameem Ahmad and Khalid Al Sayari and Bashaar Al Ibrahim and Abdullah AlKhathlan},
  year = {2022},
  journal = {Saudi Journal of Gastroenterology},
  doi = {10.4103/sjg.sjg_374_21},
  url = {https://doi.org/10.4103/sjg.sjg_374_21}
}

RIS

TY  - JOUR
TI  - The efficacy of Elbasvir/Grazoprevir fixed-dose combination for 8 weeks in HCV treatment and health-related quality of life (HRQoL) in treatment-naïve, non-cirrhotic, genotype 4-infected patients (ELEGANT-4)
AU  - Ahmad AlEid
AU  - Areej Al Balkhi
AU  - Adel Qutub
AU  - Shahem Abbarh
AU  - Abed AlLehibi
AU  - Abdullah Almtawa
AU  - Nawwaf Al Otaibi
AU  - Ahmed AlGhamdi
AU  - Adel AlGhamdi
AU  - Abdulrahman Alamr
AU  - Shameem Ahmad
AU  - Khalid Al Sayari
AU  - Bashaar Al Ibrahim
AU  - Abdullah AlKhathlan
PY  - 2022
JO  - Saudi Journal of Gastroenterology
DO  - 10.4103/sjg.sjg_374_21
UR  - https://doi.org/10.4103/sjg.sjg_374_21
ER  -

APA

AlEid, A., Balkhi, A. A., Qutub, A., Abbarh, S., AlLehibi, A., Almtawa, A., Otaibi, N. A., AlGhamdi, A., AlGhamdi, A., Alamr, A., Ahmad, S., Sayari, K. A., Ibrahim, B. A., & AlKhathlan, A. (2022). The efficacy of Elbasvir/Grazoprevir fixed-dose combination for 8 weeks in HCV treatment and health-related quality of life (HRQoL) in treatment-naïve, non-cirrhotic, genotype 4-infected patients (ELEGANT-4). Saudi Journal of Gastroenterology. https://doi.org/10.4103/sjg.sjg_374_21

Source records

crossref · retrieved 2026-09-26T20:49:13.488Z